Duloxetine A Review of its Pharmacology and Use in Chronic Pain Management

被引:46
作者
Bellingham, Geoff A.
Peng, Philip W. H. [1 ]
机构
[1] Univ Hlth Network, Toronto Western Hosp, Dept Anesthesia, Toronto, ON M5T 2S8, Canada
关键词
MAJOR DEPRESSIVE DISORDER; NORADRENERGIC REUPTAKE INHIBITOR; PERIPHERAL NEUROPATHIC PAIN; TRIAL COMPARING DULOXETINE; HEPATIC SAFETY PROFILE; DOUBLE-BLIND; SEROTONIN SYNDROME; ANIMAL-MODELS; FIBROMYALGIA; PLACEBO;
D O I
10.1097/AAP.0b013e3181df2645
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Duloxetine is a serotonin and norepinephrine reuptake inhibitor that possesses antidepressant and pain-relieving properties. Compared with other antidepressants, it has a high affinity for both norepinephrine and serotonin reuptake transporters, which are relatively balanced. Analgesic onset has been observed within the first week of administration in randomized controlled trials and is likely obtained by enhancing the tone of the descending pain inhibition pathways of the central nervous system. Randomized trials have documented significant analgesic effects for managing chronic pain associated with fibromyalgia and diabetic peripheral neuropathic pain. Studies have also suggested that pain associated with major depressive disorder can be reduced with this medication. Modest effects for headache, osteoarthritic pain, and pain secondary to Parkinson disease have also been documented, but data are obtained from single-blinded or open-label trials that require further corroboration with larger randomized studies. Duloxetine has not yet been directly compared with other antidepressants or anticonvulsants for the treatment of pain syndromes.
引用
收藏
页码:294 / 303
页数:10
相关论文
共 82 条
[1]   Consensus guidelines: Treatment planning and options [J].
Argoff, CE ;
Backonja, MM ;
Belgrade, MJ ;
Bennett, GJ ;
Clark, MR ;
Cole, BE ;
Fishbain, DA ;
Irving, GA ;
McCarberg, BH ;
McLean, MJ .
MAYO CLINIC PROCEEDINGS, 2006, 81 (04) :S12-S25
[2]   A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder [J].
Arnold, LM ;
Rosen, A ;
Pritchett, YL ;
D'Souza, DN ;
Goldstein, DJ ;
Iyengar, S ;
Wernicke, JF .
PAIN, 2005, 119 (1-3) :5-15
[3]   A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder [J].
Arnold, LM ;
Lu, YL ;
Crofford, LJ ;
Wohlreich, M ;
Detke, MJ ;
Iyengar, S ;
Goldstein, DJ .
ARTHRITIS AND RHEUMATISM, 2004, 50 (09) :2974-2984
[4]   EFNS guidelines on pharmacological treatment of neuropathic pain [J].
Attal, N. ;
Cruccu, G. ;
Haanpaa, M. ;
Hansson, P. ;
Jensen, T. S. ;
Nurmikko, T. ;
Sampaio, C. ;
Sindrup, S. ;
Wiffen, P. .
EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 (11) :1153-1169
[5]   Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters [J].
Béïque, JC ;
Lavoie, N ;
de Montigny, C ;
Debonnel, G .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 349 (01) :129-132
[6]   A case of apical ballooning cardiomyopathy associated with duloxetine [J].
Bergman, Benjamin R. ;
Reynolds, Harmony R. ;
Skolnick, Adam H. ;
Castillo, Demetrio .
ANNALS OF INTERNAL MEDICINE, 2008, 149 (03) :218-219
[7]   Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain [J].
Bomholt, SF ;
Mikkelsen, JD ;
Blackburn-Munro, G .
NEUROPHARMACOLOGY, 2005, 48 (02) :252-263
[8]   Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder [J].
Brannan, SK ;
Mallinckrodt, CH ;
Brown, EB ;
Wohlreich, MM ;
Watkin, JG ;
Schatzberg, AF .
JOURNAL OF PSYCHIATRIC RESEARCH, 2005, 39 (01) :43-53
[9]   Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: A Randomized controlled trial [J].
Brecht, Stephan ;
Courtecuisse, Christine ;
Debieuvre, Catherine ;
Croenlein, Jens ;
Desaiah, Durisala ;
Raskin, Joel ;
Petit, Claude ;
Dernyttenaere, Koen .
JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 (11) :1707-1716
[10]   The dual transporter inhibitor duloxetine: A review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression [J].
Bymaster, FP ;
Lee, TC ;
Knadler, MP ;
Detke, MJ ;
Iyengar, S .
CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (12) :1475-1493